However, given concerns about waning immunity and the emergence of novel variants, there is interest in understanding the potential role of alternative dosing strategies for these vaccines to augment or prolong their protective effect, including (but not limited to): administration of additional doses of each vaccine, schedules containing different products (“mix and match”) and modified dosing intervals.Īlthough individuals aged 12 years and up (for Pfizer-BioNTech) and individuals aged 18 years and up (for Moderna) may receive the second dose in the primary series at extended intervals, shorter intervals are still recommended for moderately to severely immunocompromised individuals, adults aged 65 and older, and others who need rapid protection. No current guidance from FDA or from CDC authorizes or recommends Novavax NVX-CoV2373 to be used as a booster dose, or for the primary series of NVX-CoV2373 to be followed by a booster.Īll four vaccines have been demonstrated to be highly effective against severe outcomes related to COVID-19 in clinical trials and post-authorization observational studies. The dose contains 5mcg of antigen and 50mcg of the adjuvant, Matrix-M. The Novavax COVID-19 vaccine is FDA-authorized for emergency use as a two-dose series administered 21 days apart for adults 18 years and older.The Johnson & Johnson/Janssen COVID-19 vaccine is FDA-authorized for emergency use as a one-dose series for adults 18 years and older who are medically ineligible for another COVID-19 vaccine or who otherwise would not receive any other COVID-19 vaccine.The dose is 100 mcg for ages 12 years and up, 50mcg for ages 6 to 11 years, and 25mcg for ages 6 months to 5 years. It is also authorized for emergency use in individuals aged 6 months–17 years. Individuals may receive the second dose in the primary series 4-8 weeks after the first dose in the primary series. The Moderna COVID-19 vaccine is FDA-a pproved for use as a two-dose series administered 28 days apart to adults 18 years and older.Individuals 12 years old and older may receive the second dose in the primary series 3-8 weeks after the first dose in the primary series. It is al so authorized for emergency use in children aged 6 months–4 years as a three-dose series, with the first 2 doses administered 21 days apart and the third dose administered at least 60 days after dose 2. The vaccine dose is 30 mcg for ages 12 and up, but is 10 mcg for children 5-11 years old and 3mcg for children 6 months–4 years old. The Pfizer-BioNTech COVID-19 vaccine is FDA-approved for use as a two-dose series administered 21 days apart to adolescents and adults 16 years and older and is authorized for emergency use in children ages 5-15 using the same schedule.The four COVID-19 vaccines available for use in the U.S.
It is not comprehensive of all data related to this subject. The following is a curated review of key information and literature about this topic.